Implantable cardioverter-defibrillator

DEVICE4 trials

Sponsors

Biotronik SE & Co. KG, University of Turku, Rennes University Hospital

Conditions

EmbolismHeart Failure, CongestiveHemorrhageSevere Cardiac InsufficiencyTachyarrhythmiaThrombosis

Phase 4

Study to Verify Proper Detection of Supraventricular Tachyarrhythmia With Single-Lead Dual-Chamber Implantable Cardioverter-Defibrillators (ADRIA)

CompletedNCT00324662

Biotronik SE & Co. KGTachyarrhythmia

Start: 2003-08-31End: 2008-07-31Target: 260Updated: 2008-09-30

Anticoagulant Therapy During Pacemaker Implantation

CompletedNCT00479362

University of TurkuEmbolism, Hemorrhage, Thrombosis

Start: 2005-09-30End: 2012-09-30Updated: 2012-09-17

Unknown Phase

Home Monitoring in Cardiac Resynchronisation Therapy

CompletedNCT00376116

Biotronik SE & Co. KGHeart Failure, Congestive

Start: 2005-03-31End: 2008-11-30Updated: 2008-11-17

Determination of Risk Factors of Ventricular Arrhythmias (VAs) After Implantation of Continuous Flow Left Ventricular Assist Device With Continuous Flow Left Ventricular Assist Device (CF-LVAD)

CompletedNCT02873169

Rennes University HospitalSevere Cardiac Insufficiency

Start: 2015-09-30End: 2016-12-31Updated: 2017-10-20

Related Papers

Early Ventricular Arrhythmias After LVAD Implantation Is the Strongest Predictor of 30-Day Post-Operative Mortality.

2019-08-1929 citations

Predictors and Clinical Impact of Late Ventricular Arrhythmias in Patients With Continuous-Flow Left Ventricular Assist Devices.

2018-07-2562 citations

Potential value of automated daily screening of cardiac resynchronization therapy defibrillator diagnostics for prediction of major cardiovascular events: results from Home-CARE (Home Monitoring in Cardiac Resynchronization Therapy) study.

2011-09-0137 citations